COMMUNIQUÉS West-GlobeNewswire

Integra LifeSciences Reports First Quarter 2025 Financial Results
05/05/2025
PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending [...]
Best Male Fertility Supplements: Best Vitamin Supplements For Male Fertility And Male Conception, Fertilaid For Men, Best Sperm Motility Supplement, Best Coq10 For Male Fertility (Semenoll)
05/05/2025
Glasgow, May 05, 2025 (GLOBE NEWSWIRE) -- Boosting Male Fertility Naturally: Diet, Lifestyle & Supplements Having a diet rich in vitamins and minerals—along with a healthy lifestyle that includes proper sleep, [...]
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
05/05/2025
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA cancer [...]
Vyvamind Under Review: Does Vyvamind Work? Best Adderall Alternative Nootropic Supplement
05/05/2025
Is Vyvamind the best Adderall alternative? Discover how this natural nootropic supplement boosts focus, energy, and mental clarity—backed by science and real reviews. Albany, New York, May 05, 2025 (GLOBE NEWSWIRE) -- [...]
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
05/05/2025
AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular [...]
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
05/05/2025
Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months active drug continued [...]
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
05/05/2025
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete [...]
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
05/05/2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal [...]
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
05/05/2025
WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
05/05/2025
Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001 in patients with heavily pretreated multiple myeloma to be presented at the 2025 ASCO Annual Meeting NEW YORK, May 05, 2025 (GLOBE [...]
Microbix’s Clot-Buster Drug Project Advances
05/05/2025
Sequel Pharma Executes Agreement with CDMO for Drug Product Manufacturing MISSISSAUGA, Ontario, May 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator [...]
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®
05/05/2025
Program A imed at G enerating K ey D ata in S upport of the B enefits of CYTOGAM® in the Management of Cytomegalovirus ( CMV ) in Solid Organ Transplantation A Total of 10 Studies will be Conducted in Collaboration with [...]
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05/05/2025
The U.S. FDA has approved SELARSDI ™ (ustekinumab- aekn ) as interchangeable with the reference biologic Stelara ® (ustekinumab) in all presentations matching the reference product , effective as of April 30, 2025 [...]
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model
05/05/2025
Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI [...]
IRADIMED CORPORATION Announces First Quarter 2025 Financial Results
05/05/2025
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or [...]
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05/05/2025
The U.S. FDA has approved SELARSDI ™ (ustekinumab- aekn ) as interchangeable with the reference biologic Stelara ® (ustekinumab) in all presentations matching the reference product , effective as of April 30, 2025 [...]
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
05/05/2025
Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a [...]
TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance
05/05/2025
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 [...]
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
05/05/2025
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q 2025 net product [...]

Pages